Avoid common mistakes on your manuscript.
To the editor
Breast cancer incidence in Asia has doubled over the past 10 years and is one of the highest in Hong Kong [1]. Studies in western populations have found differences in breast cancer epidemiology between Asian and Caucasian populations, potentially due to interactions between different lifestyle and genetic characteristics [2–4]. As the genetic predisposition to breast cancer is increasingly understood, it has been suggested that there are differences in different ethnic populations. To date, only a few investigations on the spectrum of BRCA [5, 6] mutations in Chinese populations have been performed, most of which were performed in single institutions or a small number of medical centers [7–9]. Some studied only the BRCA1 gene [10, 11] and most did not perform mutational screening using conventional full gene sequencing [12, 13].
Between March 2007 and February 2008, patients with breast and/or ovarian cancer were recruited from the Hong Kong Hereditary Breast Cancer Family Registry, which was formed in March 2007. In this Registry, all patients were recruited from 11 government-based hospitals, private hospitals, and clinics that cover all three areas of Hong Kong. Sequence analysis of all exons in BRCA1 and BRCA2 of a total of 119 high-risk female probands were conducted. The mean age at diagnosis of breast cancer was 41.6 years (range 23–73) and that of ovarian cancer was 43.8 years (range 23–65). All probands were from Chinese ancestry and 81.5% were from Guangdong province of southern China. Our sequencing results identified 22 (18.5%) deleterious BRCA gene mutations. A total of 8 (8/119, 6.7%) gene mutations were in BRCA1 and 14 (14/119, 11.8%) in BRCA2. The spectra of mutations are illustrated in Table 1. Among those mutations detected, only one BRCA1 (c.4987_5277del) and one BRCA2 (c.8633_8755del) deletion mutation were found by multiplex ligation-dependent probe amplification (MLPA) and confirmed by DNA sequencing.
Of the 22 deleterious mutations found, seven (31.8%) were new mutations, which have not been published in the Breast Information Core Database of National Institute of Health (BIC) as described in Table 1. All the seven new mutations cause sequence frame-shift, leading to early termination of translation for protein products. Of these new mutations, four were in BRCA2 and three were in BRCA1. Reports have found a high frequency of genetic sequence variants in different ethnic populations [8, 11, 14, 15]. This is likely due to the limited knowledge of the mutation spectrum in different ethnic populations, where BRCA testing has not been widely performed [16]. Since we have identified a number of missense mutations and synonymous polymorphisms of unknown significance, further functional analysis and disease risk association studies are needed to be performed, in the future, to characterize the clinical significance of these mutations.
One recurrent BRCA2 mutation was found in four probands in this cohort and accounted for 28.6% of BRCA2 mutations and 18.2% of all BRCA mutations. The recurrent mutation c.3109C>T; p.Gln1037X in exon 11 of BRCA 2 was found in four unrelated probands in this cohort. We have also seen this recurrent mutation in two other independent Hong Kong Chinese male breast cancer patients from another patient cohort. Accordingly, this recurrent mutation was identified in a total of six independent individuals (proband# 45, 57, 91, 118, and male patient# M1, M2). This mutation resulted in the creation of an early termination codon and a truncated BRCA2 protein product. In order to confirm the founder effect, haplotype analysis using eight microsatellite polymorphic markers (D13S1304, D13S217, D13S289, D13S1699, D13S1698, D13S171, D13S1695, and D13S267) that are in close proximity to BRCA2 was performed in the 6 index cases and 8 family members from 3 index cases and 50 unrelated Chinese individuals. A common haplotype was found to co-segregate together with the mutation, but not found in the mutation negative family members of the probands. Based on the haplotype analysis of our control cohort of 50 unrelated Chinese individuals, we estimated the random population frequency of the shared haplotype is ~1.13 in 10,000. Recombination event is observed in two of the six individuals for markers D13S217 and D13S267 which are susceptible for recombination events, as their recombination frequency are ~3.53 and 1.36% respectively. The haplotype analysis confirmed the mutation c.3109C>T, a founder mutation of southern Chinese.
Variations in techniques of mutation detection can result in significant inconsistencies between studies [3, 17, 18]. In addition, large-scale rearrangements in BRCA1 have been reported to be as frequent as 2–12% in high risk families [19, 20]. Among all BRCA1 mutations, 7–40% may be due to large rearrangements [21, 22] and similarly in 2–8% of BRCA2 families [23–25]. Recent studies have found that without analysis of genomic rearrangements some mutations may be missed [20, 26]. There is increasing data suggesting that large genomic alterations may be more common in specific ethnic populations [21, 27]. We have chosen to perform MLPA screening in all our probands to improve the under reporting of BRCA1/2 mutations, where knowledge of Chinese race is already limited. Indeed one (4.8%) BRCA1 and 1 (4.8%) BRCA2 large deletion were found only by MLPA, and overall identification rate of 9.5% of all the BRCA mutations was found in the probands of this cohort. Hence, although conventional DNA sequencing is laborious and costly for such large size of BRCA1 and BRCA2, we believe that the combination of conventional sequencing with MLPA is currently one of the best choices for evaluating a wide range of genomic alterations in BRCA1 and BRCA2 genes.
In conclusion, 18.5% of our high risk Chinese cohort carries the BRCA mutation. We identified seven (7/22, 31.8%) new deleterious mutations and also confirmed and reported a BRCA2 founder mutation in our Hong Kong Chinese cohort, which mainly consist of southern Chinese. Knowing the frequency and range of mutations in a specific ethnic population provides important factor in genetic counseling and cancer risk assessment. The discovery of this founder mutation may provide a cost-effective option to screen southern Chinese population.
References
The Hong Kong Cancer Registry (2005) Fast stats for female breast cancer. http://www3.ha.org.hk/cancereg/
John EM et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298(24):2869–2876. doi:10.1001/jama.298.24.2869
Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7(12):937–948. doi:10.1038/nrc2054
Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11(7):601–607
Katagiri T et al (1998) High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Hum Genet 43(1):42–48. doi:10.1007/s100380050035
Wooster R et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792. doi:10.1038/378789a0
Song CG et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 132(10):617–626. doi:10.1007/s00432-006-0105-9
Zhi X et al (2002) BRCA1 and BRCA2 sequence variants in Chinese breast cancer families. Hum Mutat 20(6):474. doi:10.1002/humu.9083
Hu Z et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22(1):104. doi:10.1002/humu.9156
Sng JH et al (2000) The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 82(3):538–542. doi:10.1054/bjoc.1999.0960
Tang NL et al (2001) Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. Clin Chim Acta 313(1–2):179–185. doi:10.1016/S0009-8981(01)00671-4
Li WF et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99–109. doi:10.1007/s10549-008-9708-3
Chen W, et al. (2008) BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-008-0066-6
Zhou YZ et al (2004) Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people. Zhonghua Yi Xue Za Zhi 84(4):294–298
Ho GH et al (2000) Novel germline BRCA1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years. Cancer 89(4):811–816. doi:10.1002/1097-0142(20000815)89:4<811::AID-CNCR13>3.0.CO;2-R
Nanda R et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294(15):1925–1933. doi:10.1001/jama.294.15.1925
Andrulis IL et al (2002) Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 20(1):65–73. doi:10.1002/humu.10097
Sevilla C et al (2002) Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 10(10):599–606. doi:10.1038/sj.ejhg.5200854
Hendrickson BC et al (2005) Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20, 000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer 43(3):309–313. doi:10.1002/gcc.20189
Walsh T et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388. doi:10.1001/jama.295.12.1379
Hogervorst FB et al (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63(7):1449–1453
Montagna M et al (2003) Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 12(9):1055–1061. doi:10.1093/hmg/ddg120
Tournier I et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64(22):8143–8147. doi:10.1158/0008-5472.CAN-04-2467
Casilli F et al (2006) The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet 43(9):e49. doi:10.1136/jmg.2005.040212
Sekine M et al (2001) Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7(10):3144–3150
Gutierrez-Enriquez S et al (2007) Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat 103(1):103–107. doi:10.1007/s10549-006-9376-8
Mazoyer S (2005) Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25(5):415–422. doi:10.1002/humu.20169
Acknowledgments
We sincerely thank Dr. Ellen Li Charitable Foundation, The Kuok Foundation, Hong Kong Cancer Fund, National Institute of Health 1R03CA130065, and North California Cancer Center for their support. We also like to thank the research staff at Hong Kong Sanatorium and Hospital who have contributed to this project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kwong, A., Wong, L.P., Wong, H.N. et al. A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117, 683–686 (2009). https://doi.org/10.1007/s10549-009-0385-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0385-2